Relative <scp>MYC</scp> downregulation and <scp>RUNX2</scp> upregulation orchestrate partial epithelial‐mesenchymal transition in colorectal cancer tumor budding and poorly differentiated clusters

Tumor budding and poorly differentiated clusters are key prognostic indicators in colorectal cancer, yet the molecular mechanisms underlying their formation remain incompletely characterized. Using the GeoMx Digital Spatial Profiler, we analyzed gene expression profiles across tubular components, transitional zones, and tumor budding and poorly differentiated cluster regions in 12 colorectal cancer cases. While histopathological assessment revealed no definitive evidence of complete epithelial-mesenchymal transition in tumor budding or poorly differentiated clusters, transcriptional analysis demonstrated significant upregulation of epithelial-mesenchymal transition-related genes (ZEB1, ZEB2, SNAI2) alongside maintained epithelial marker expression, indicating a partial epithelial-mesenchymal transition phenotype. Tumor budding and poorly differentiated cluster regions showed reduced proliferative activity with significant downregulation of MYC and its target genes involved in protein synthesis and cell cycle progression. Conversely, RUNX2 and its targets were significantly upregulated in tumor budding and poorly differentiated cluster regions, particularly genes mediating cell adhesion, migration, and extracellular matrix interactions. KRT80 showed striking upregulation in tumor budding and poorly differentiated cluster regions, correlating with RUNX2 expression. This reciprocal pattern of MYC downregulation and RUNX2 upregulation appears to contribute to maintaining the hybrid epithelial-mesenchymal state characteristic of tumor budding and poorly differentiated cluster regions. Our findings reveal that the formation of these regions involves transcriptional changes preceding morphological alterations, with RUNX2 potentially driving this invasive phenotype while preserving epithelial features. These insights may enhance our understanding of the mechanisms driving colorectal cancer progression and identify potential therapeutic targets for aggressive disease. © 2026 The Pathological Society of Great Britain and Ireland.